TRANSFUSION TRIAL TO PREVENT PLATELET ALLOIMMUNIZATIONS

预防血小板同种免疫的输血试验

• 批准号: 3553346
• 负责人: WENDELL F ROSSE
• 金额: $ 7.5万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1989
• 资助国家: 美国
• 起止时间: 1989-08-01 至 1993-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3553346
• 关键词: acute leukemia; antibody specificity; antigen presenting cell; blood donor; blood filtration; cooperative study; epidemiology; genetic markers; histocompatibility; histocompatibility antigens; homologous transplantation; human subject; human therapy evaluation; immunofluorescence technique; leukocyte antigen typing; major histocompatibility complex; platelet transfusion; platelets; radiation immunosuppression; radioimmunoassay; ultraviolet radiation

Alloimmunization to antigens on platelets is one of the most severe limiting factors in platelet transfusion. In this application to become a member of a cooperative trial for the prevention of alloimmunization, we propose two strategies which might limit alloimmunization from this source in patients treated for acute non-lymphocytic leukemia: 1. selection of platelet donors by matching HLA antigens, particularly the so-called "public" antigens; 2. removal of leukocytes from platelet products by filtration. In a cooperative study, we would be able to implement other strategies if they were selected. We also propose methods for following the development of alloimmunization to both HLA and platelet-specific antigens and for determining the epidemiology of alloimmunization.

对血小板抗原的同种免疫是最严重的免疫反应之一 血小板输注的限制因素。在这个应用程序中成为 作为预防同种免疫合作试验的成员，我们 提出两种可能限制同种免疫的策略 治疗急性非淋巴细胞白血病患者的来源： 1. 通过匹配HLA抗原来选择血小板捐献者，特别是 所谓的“公共”抗原； 2. 去除血小板中的白细胞 通过过滤得到的产品。在合作研究中，我们能够 如果选择了其他策略，则实施它们。 我们还提出了跟踪同种免疫发展的方法 HLA 和血小板特异性抗原并确定 同种免疫的流行病学。